The binding of human complement component C4 to antibody-antigen aggregates
- PMID: 6906229
- PMCID: PMC1161918
- DOI: 10.1042/bj1890067
The binding of human complement component C4 to antibody-antigen aggregates
Abstract
The binding of human complement component C4 to antibody-antigen aggregates and the nature of the interaction have been investigated. When antibody-antigen aggregates with optimal C1 bound are incubated with C4, the C4 is rapidly cleaved to C4b, but only a small fraction (1-2%) is bound to the aggregates, the rest remaining in the fluid phase as inactive C4b. It has been found that C4b and th antibody form a very stable complex, due probably to the formation of a covalent bond. On reduction of the C4b-immunoglobulin G (IgG) complex, the beta and gamma chains, but not the alpha' chain, of C4b are released together with all the light chain, but only about half of the heavy chain of IgG. The reduced aggregates contain two main higher-molecular-weight complexes, one shown by the use of radioactive components to contain both IgG and C4b and probably therefore the alpha' chain of C4b and the heavy chain of IgG, and the other only C4b and probably an alpha' chain dimer. The aggregates with bound C1 and C4b show maximal C3 convertase activity, in the presence of excess C2, when the alpha'-H chain component is in relatively highest amounts. When C4 is incubated with C1s in the absence of aggregates, up to 15% of a C4b dimer is formed, which on reduction gives an alpha' chain complex, probably a dimer. The apparent covalent interaction between C4b and IgG and between C4b and other C4b molecules cannot be inhibited by iodoacetamide and hence cannot be catalysed by transglutaminase (factor XIII). The reaction is, however, inhibited by cadaverine and putrescine and 14C-labelled putrescine is incorporated into C4, again by a strong, probably covalent, bond. It is suggested that a reactive group, possibly an acyl group, is generated when C4 is activated by C1 and that this reactive group can react with IgG, with another C4 molecule, or with water.
Similar articles
-
Formation of covalent complexes between the fourth component of human complement and IgG immune aggregates.Complement. 1987;4(1):21-32. doi: 10.1159/000463004. Complement. 1987. PMID: 3568629
-
Binding of human C4 to C-reactive protein-pneumococcal C-polysaccharide complexes during activation of the classical complement pathway.Mol Immunol. 1983 Nov;20(11):1201-7. doi: 10.1016/0161-5890(83)90143-8. Mol Immunol. 1983. PMID: 6558418
-
The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.Biochem J. 1981 May 1;195(2):471-80. doi: 10.1042/bj1950471. Biochem J. 1981. PMID: 7316962 Free PMC article.
-
The Croonian Lecture, 1980. The complex proteases of the complement system.Proc R Soc Lond B Biol Sci. 1980 Nov 28;210(1181):477-98. doi: 10.1098/rspb.1980.0148. Proc R Soc Lond B Biol Sci. 1980. PMID: 6110208 Review.
-
The internal thioester and the covalent binding properties of the complement proteins C3 and C4.Protein Sci. 1997 Feb;6(2):263-74. doi: 10.1002/pro.5560060201. Protein Sci. 1997. PMID: 9041627 Free PMC article. Review.
Cited by
-
The role of complement in the stimulation of lysosomal enzyme release by polymorphonuclear leucocytes induced by immune complexes of IgG and of IgM.Immunology. 1988 Oct;65(2):171-5. Immunology. 1988. PMID: 3192269 Free PMC article.
-
The binding of human complement proteins C5, factor B, beta 1H and properdin to complement fragment C3b on zymosan.Biochem J. 1981 Dec 1;199(3):485-96. doi: 10.1042/bj1990485. Biochem J. 1981. PMID: 6462133 Free PMC article.
-
Human complement component C4. Structural studies on the fragments derived from C4b by cleavage with C3b inactivator.Biochem J. 1981 Nov 1;199(2):351-7. doi: 10.1042/bj1990351. Biochem J. 1981. PMID: 6978710 Free PMC article.
-
Soluble C3 proconvertase and convertase of the classical pathway of human complement. Conditions of stabilization in vitro.Biochem J. 1985 Mar 1;226(2):429-36. doi: 10.1042/bj2260429. Biochem J. 1985. PMID: 3922352 Free PMC article.
-
A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b.Blood Adv. 2017 Mar 14;1(8):504-515. doi: 10.1182/bloodadvances.2016001917. eCollection 2017 Mar 14. Blood Adv. 2017. PMID: 29296968 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous